|
2. Ustekinumab dosing individualization in Crohn's disease guided by a population pharmacokinetic-pharmacodynamic modelJurij Zdovc, Jurij Hanžel, Borut Štabuc, Tomaž Vovk, Barbara Ostanek, David Drobne, Iztok Grabnar, 2021, izvirni znanstveni članek Ključne besede: ustekinumab, inflammatory bowel disease, fecal calprotectin, pharmacokinetics-pharmacodynamics, therapeutic drug monitoring
Celotno besedilo (datoteka, 1,20 MB) Gradivo ima več datotek! Več... |
3. Expression of cytokine-coding genes BMP8B, LEFTY1 and INSL5 could distinguish between ulcerative colitis and Crohn's diseaseDaša Jevšinek Skok, Nina Hauptman, Miha Jerala, Nina Zidar, 2021, izvirni znanstveni članek Ključne besede: inflammatory bowel disease, ulcerative colitis, Crohn's disease, inflammatory cytokines, expression, bioinformatics approach, experimental validation
Celotno besedilo (datoteka, 2,54 MB) Gradivo ima več datotek! Več... |
4. Expression of fibrosis-related genes in liver and kidney fibrosis in comparison to inflammatory bowel diseasesMiha Jerala, Nina Hauptman, Nika Kojc, Nina Zidar, 2022, izvirni znanstveni članek Ključne besede: inflammatory bowel diseases, fibrosis, Crohn’s disease, ulcerative colitis, gene expression
Celotno besedilo (datoteka, 1,24 MB) Gradivo ima več datotek! Več... |
5. Multiple switches from the originator infliximab to biosimilars is effective and safe in inflammatory bowel diseaseJurij Hanžel, Jeroen M. Jansen, Rinze W. F. ter Steege, Krisztina B. Gecse, Geert R. D'Haens, 2022, izvirni znanstveni članek Ključne besede: SB2, CT-P13, multiple switches, Crohn's disease, inflammatory bowel disease, ulcerative colitis, adults, feces, c-reactive protein, infliximab, adverse event, leukocyte l1 antigen complex, infusion procedures, biosimilar pharmaceuticals, disease remission, imputation, antidrug antibody, infliximab-dyyb
Celotno besedilo (datoteka, 608,73 KB) Gradivo ima več datotek! Več... |
6. Pharmacokinetic-pharmacodynamic model of vedolizumab for targeting endoscopic remission in patients with Crohn diseaseJurij Hanžel, Erwin Dressen, Séverine Vermeire, Mark Löwenberg, Frank Hoentjen, Peter Bossuyt, Esmé Clasquin, Filip J. Baert, Geert R. D'Haens, Ron Mathôt, 2022, izvirni znanstveni članek Ključne besede: therapeutic drug monitoring, exposure-response, pharmacometrics, inflammatory bowel disease, Crohn's disease, drug clearance, endoscopy, pharmacodynamics, infusion procedures, disease remission, vedolizumab, therapy
Celotno besedilo (datoteka, 2,05 MB) Gradivo ima več datotek! Več... |
7. Oxidative stress-related biomarkers as promising indicators of inflammatory bowel disease activityArmando Tratenšek, Igor Locatelli, Iztok Grabnar, David Drobne, Tomaž Vovk, 2024, izvirni znanstveni članek Ključne besede: inflammatory bowel disease, ulcerative colitis, Crohn's disease, oxidative stress, biomarker, meta-analysis
Celotno besedilo (datoteka, 5,83 MB) Gradivo ima več datotek! Več... |
8. Smart bionanomaterials for treatment and diagnosis of inflammatory bowel diseaseSpase Stojanov, Aleš Berlec, 2024, pregledni znanstveni članek Ključne besede: bionanomaterials, responsive materials, gut microbiota, smart bionanomaterials, inflammatory bowel disease, probiotics
Celotno besedilo (datoteka, 2,11 MB) Gradivo ima več datotek! Več... |
9. Case reportAna Klinc, Urh Grošelj, Matej Mlinarič, Matjaž Homan, Gašper Markelj, Ajda Mezek Novak, Andreja Širca-Čampa, Jaka Šikonja, Tadej Battelino, Mojca Žerjav-Tanšek, Ana Drole Torkar, 2024, drugi znanstveni članki Ključne besede: glycogen storage disease type 1B, GSD-1b, empagliflozin, SGLT2 inhibitor, neutropenia, inflammatory bowel disease, case series
Celotno besedilo (datoteka, 1,02 MB) Gradivo ima več datotek! Več... |
